GS030-DP
Asset
Delivers a light-sensitive opsin to retinal ganglion cells, enabling responses to light stimulation.
- Stage
- Phase 1
- Modality
- Gene therapy
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Non-syndromic retinitis pigmentosa
Phase 1, Active not recruiting, NCT03326336, clinicaltrials.gov, 10 Oct 2026
In the full profile
- Owner and partners1
- Trials1
Every asset’s record: target, stage, trials and the evidence behind it.